Health insurers have new grounds to limit its use because the FDA recommended that only patients who have failed other therapies -- such as Schering AG
drug Betaseron or Copaxone, made by Teva Pharmaceutical Industries Ltd. -- can move to Tysabri.
"What the FDA did yesterday, they went against the recommendations of the (FDA) advisory committee which said it should be approved first line therapy, so absolutely they (insurers) will not allow it unless they failed standard therapy," said Andrea Witt, an analyst at Decision Resources, a market research firm.
Biogen said most companies covered Tysabri in some way before the withdrawal and has been lobbying insurers ahead of the pending comeback. Link
technorati tag: multiple sclerosis